Pseudoclaudication: Is it related to claudication?
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - April 14, 2014 Category: Consumer Health News Source Type: news
Fear of falling in claudicants and its relationship to physical ability, balance, and quality of life - Lane RA, Mazari F, Mockford KA, Vanicek N, Chetter IC, Coughlin PA.
OBJECTIVES: Intermittent claudication is associated with poor physical function, quality of life (QoL), and balance impairment. Fear of falling (FoF) is a recognized contributing factor to poor physical ability. Any link between claudication and FoF is yet... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - February 3, 2014 Category: Global & Universal Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Study may bust myth of 'fat and fit' healthy obesity
Conclusion
This meta-analysis provides further evidence about the known risk factors for cardiovascular disease and mortality.
What this study adds is the indication that people who are metabolically unhealthy regardless of their weight are at increased risk.
However, interestingly, no increase in risk was seen for the category of people who are metabolically healthy though overweight.
A strength of this meta-analysis is the large sample size. However, the results should be interpreted with caution as:
The studies did not use the same criteria for assessing metabolic status.
The studies did not use the same cri...
Source: NHS News Feed - December 4, 2013 Category: Consumer Health News Tags: Food/diet Lifestyle/exercise Obesity Source Type: news
AHA: Procedure Plus Exercise ERASEs PAD (CME/CE)
DALLAS (MedPage Today) -- The combination of endovascular revascularization and a supervised exercise program for patients with peripheral artery disease reduced claudication pain and increased walking distance, researchers reported. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 20, 2013 Category: Cardiology Source Type: news
EMA recommends restricting cilostazol use for PAD
The Europeans Medicines Agency has recommended restricting the use of cilostazol in patients with intermittent claudication. Use should be avoided in those with cardiac problems or on dual anticoagulants. (Source: theHeart.org)
Source: theHeart.org - March 22, 2013 Category: Cardiology Source Type: news
EMA Recommends Restricting Cilostazol Use for PADEMA Recommends Restricting Cilostazol Use for PAD
The Europeans Medicines Agency has recommended restricting the use of cilostazol in patients with intermittent claudication. Use should be avoided in those with cardiac problems or on dual anticoagulants News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 22, 2013 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news
European Medicines Agency recommends restricting use of cilostazol-containing medicines
Source: EMA
Area: News
Following a review of the current evidence, the European Medicines Agency's (EMA) Committee on Medicinal Products for Human Use (CHMP) has recommended that the use of cilostazol in the treatment of intermittent claudication should be restricted with a range of new measures aimed at targeting a patient population in which there are clinical benefits, and at the same time minimising important risks.
The Spanish Agency for Medicines and Health Products (AEMPS) asked the CHMP to carry out a review of cilostazol following a number of reports of serious suspected adverse effects, in particular...
Source: NeLM - Cardiovascular Medicine - March 22, 2013 Category: Cardiology Source Type: news
ACE inhibitor helps in intermittent claudication
Patients taking ramipril walked for longer without painRelated items from OnMedicaRecurrent stroke more likely at very low BPPolypill could halve cardiovascular events Caution urged over intensive glucose controlDaily aspirin use linked to major bleedingStroke rate higher in HIV patients (Source: OnMedica Latest News)
Source: OnMedica Latest News - February 7, 2013 Category: UK Health Source Type: news
Ramipril Improves Walking For People With Peripheral Artery Disease
Pain-free walking as well as length of walk both improved greatly in patients with claudication following treatment with the ACE blocker ramipril. The new study, published in JAMA, revealed pain-free walking rose by 60 percent on average and maximum walking time doubled following six months of treatment with the ACE inhibitor. Close to every secondary result also improved with ramipril versus placebo, such as functional areas of health-related quality of life and the ankle-brachial index (ABI) - an impairment scale for peripheral arterial disease (PAD)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 6, 2013 Category: Consumer Health News Tags: Vascular Source Type: news
Ramipril Improves Walking For People With PAD
Pain-free walking as well as length of walk both improved greatly in patients with claudication following treatment with the ACE blocker ramipril. The new study, published in JAMA, revealed pain-free walking rose by 60 percent on average and maximum walking time doubled following six months of treatment with the ACE inhibitor. Close to every secondary result also improved with ramipril versus placebo, such as functional areas of health-related quality of life and the ankle-brachial index (ABI) - an impairment scale for peripheral arterial disease (PAD)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 6, 2013 Category: Consumer Health News Tags: Vascular Source Type: news
RCT: Effect of ramipril on walking times and QoL in patients with peripheral artery disease and intermittent claudication:
Source: JAMA
Area: News
Approximately one-third of patients with peripheral artery disease (PAD) experience intermittent claudication, with consequent loss of quality of life (QoL).
This multicentre randomised, double-blind, placebo-controlled trial evaluated the efficacy of ramipril for improving walking ability, patient-perceived walking performance, and QoL in 212 Australian patients with PAD (mean age 65.5 years).
Patients were randomised to receive ramipril (10mg/day; n = 106) or matching placebo (n = 106) for 24 weeks. Patients were observed for two prespecified primary outcomes, maximum and p...
Source: NeLM - News - February 6, 2013 Category: Drugs & Pharmacology Source Type: news
Ramipril Substantially Improved Walking Times in PAD TrialRamipril Substantially Improved Walking Times in PAD Trial
After six months, patients with peripheral artery disease and intermittent claudication who were treated with ramipril were able to walk considerably longer pain free and walk much farther on a treadmill compared with their peers who received placebo, in a new study. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 5, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
ACE inhibitor for PAD may improve pain-free walking
Among patients with peripheral artery disease and intermittent claudication (pain in the calf that comes and goes, typically felt while walking), 24 weeks of treatment with the angiotensin-converting enzyme (ACE) inhibitor ramipril was associated with improvement in pain-free and maximum walking times and the physical health aspect of quality of life, according to a new study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 5, 2013 Category: Science Source Type: news
ACE Inhibitor Improves Walking In People with Peripheral Artery Disease
Giving an ACE inhibitor to people with peripheral artery disease (PAD) and intermittent claudication reduces pain and increases walking time, according to a new study published in JAMA. Currently the pharmacologic options for this patient population are few and have limited efficacy. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 5, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
